- Home
- HEPS vs AVDL Comparison
HEPS vs AVDL Comparison
Compare HEPS & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- AVDL
- Stock Information
- Founded
- HEPS 2000
- AVDL 2015
- Country
- HEPS Turkey
- AVDL Ireland
- Employees
- HEPS N/A
- AVDL N/A
- Industry
- HEPS Catalog/Specialty Distribution
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- AVDL Health Care
- Exchange
- HEPS Nasdaq
- AVDL Nasdaq
- Market Cap
- HEPS 811.7M
- AVDL 784.6M
- IPO Year
- HEPS 2021
- AVDL 1996
- Fundamental
- Price
- HEPS $2.66
- AVDL $9.11
- Analyst Decision
- HEPS
- AVDL Strong Buy
- Analyst Count
- HEPS 0
- AVDL 6
- Target Price
- HEPS N/A
- AVDL $18.17
- AVG Volume (30 Days)
- HEPS 348.8K
- AVDL 1.3M
- Earning Date
- HEPS 06-12-2025
- AVDL 05-07-2025
- Dividend Yield
- HEPS N/A
- AVDL N/A
- EPS Growth
- HEPS N/A
- AVDL N/A
- EPS
- HEPS N/A
- AVDL N/A
- Revenue
- HEPS $1,471,066,066.00
- AVDL $194,450,000.00
- Revenue This Year
- HEPS $22.80
- AVDL $55.11
- Revenue Next Year
- HEPS $25.49
- AVDL $30.13
- P/E Ratio
- HEPS N/A
- AVDL N/A
- Revenue Growth
- HEPS 42.87
- AVDL 252.64
- 52 Week Low
- HEPS $1.71
- AVDL $6.38
- 52 Week High
- HEPS $4.05
- AVDL $17.30
- Technical
- Relative Strength Index (RSI)
- HEPS 45.42
- AVDL 53.96
- Support Level
- HEPS $2.56
- AVDL $8.77
- Resistance Level
- HEPS $2.90
- AVDL $9.31
- Average True Range (ATR)
- HEPS 0.11
- AVDL 0.41
- MACD
- HEPS 0.00
- AVDL -0.04
- Stochastic Oscillator
- HEPS 29.85
- AVDL 53.60
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.